Robert Maki
Attending Physician · New York Presbyterian Hospital
Credentials: · · · · · · ·
History
- 2023–Present
Memorial Hospital for Cancer and allied Diseases · Memorial Sloan Kettering Cancer Center
- 1995–1997
Research
Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer
New England Journal of Medicine · 2010 · 3,649 citations
A framework for advancing our understanding of cancer-associated fibroblasts
Review · Nature reviews. Cancer · 2020 · 3,123 citations
The Lancet Oncology · 2017 · 1,203 citations
- CA
70 papers
40 papers · 31 as a resident
39 papers
- MK
29 papers
- MB
28 papers
28 papers
27 papers
- WT
24 papers
Grants
- 2026–2030
Food and Drug Administration · R01
Contact PI · $345.3K · Sloan-Kettering Inst Can Research
- 2009–2011
Translational Research Studies in Clinical Trials of Novel Therapeutics for Sarco
National Cancer Institute · RC2
Contact PI · $1.2M · Sloan-Kettering Inst Can Research
Clinical trials
- 2025–2028
A Study of Pembrolizumab in People With Ultra-Rare Sarcomas
Principal investigator · Recruiting · Phase 2
Memorial Sloan Kettering Cancer Center
- 2014–2022
SARC024: A Blanket Protocol to Study Oral Regorafenib in Patients With Selected Sarcoma Subtypes
Principal investigator · Completed · Phase 2
Sarcoma Alliance for Research through Collaboration
- 2007–2010
Sunitinib in Treating Patients With Metastatic, Locally Advanced, or Locally Recurrent Sarcomas
Principal investigator · Completed · Phase 2
Memorial Sloan Kettering Cancer Center
- 2005–2011
Sorafenib in Treating Patients With Metastatic, Locally Advanced, or Recurrent Sarcoma
Principal investigator · Completed · Phase 2
National Cancer Institute (NCI)